Research & Development
Dr. Reddy's Laboratories Launches Ertapenem for Injection in the US Market
13 May 2021 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched in the USA Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of Invanz (ertapenem for injection) for injection, 1 g/vial approved by the US Food and Drug Administration (USFDA).

The Invanz brand and generic market had US sales of approximately USD 205m MAT for the most recent twelve months ending in March 2021 according to Iqvia Health (NYSE: IQV).

Dr. Reddy's Ertapenem for Injection, 1 g/vial, is available in packs of 10 vials per carton.

Dr. Reddy's is an integrated pharmaceutical company that offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.

Gland Pharma Ltd. (BSE: 543245) (NSE: GLAND) was established in 1978 in Hyderabad, has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets.

The company operates primarily under a business to business model and have an excellent track record in the development, manufacturing and marketing of complex injectables.

It has a range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology and ophthalmic solutions and also enjoys the distinction of having pioneered Heparin technology in India.


Related Headlines